微信直播

WCLC 2017专访 | Prof. Silvia Novello:我们的工作,是不断地创造更美好的生活

Published at: 2015年第1卷第S1期

晨 凌
关键词:

编者按2017年10月15-18日,第十八届世界肺癌大会(WCLC 2017)成功于在日本横滨举办。置身于全球颇负盛名的肺癌和其他胸部恶性肿瘤的多学科肿瘤学顶尖会议中,不仅可以获知该领域最新的研究成果和医疗技术方面的新进展,还可以与来自世界各地的知名专家进行互动交流。这次会议中,AME出版社十分荣幸地采访了来自University of Turin-Italy的Prof. Silvia Novello

人物聚焦:Silvia Novello

Professor Novello, MD, PhD, graduated in Medicine at the University of Turin, Italy in 1995. She then did a Postgraduate Course in Respiratory Medicine which she completed in 1999 summa cum laude. In 2006 she achieved a PhD in Human Oncology and went on doing a Postgraduate in Medical Oncology in 2010.

Professor Novello is presently Assistant Professor of Respiratory Medicine at the Department of Clinical and Biological Sciences of the University of Turin, Italy.

Her previous positions include: Fellow at S. Luigi Hospital, Clinic of Respiratory Diseases, Orbassano, Turin, from 1995 to 1999 and Clinical Fellow at the same hospital, Thoracic Oncology DH, from 1999 to 2000. From 2000 to 2001 she was Resident A at the Institut Gustave Roussy, Villejuif, France. From 2001 to 2003, Research Fellow in the Medical Experimental and Clinical Sciences area at the Thoracic Oncology Division (University of Turin), and attending Physician at the Thoracic Oncology Division, from 2004 to 2010.

Professor Novello was also Thoracic Oncology Division tutor of Educational Classes in Thoracic Oncology and Educational Classes supported by AIPO (Hospital Pulmonologist Italian Association) for Specialised Doctors in Respiratory Diseases, Thoracic Surgery and Medical Oncology.

作为一名杰出的胸部肿瘤领域里的专家,Prof. Novello在间皮瘤的研究中有较深的造诣。Prof. Novello 认为间皮瘤是一种相对罕见的肿瘤,治疗性替代物比较少。选择最佳的治疗策略需要考虑这些不同的因素:肿瘤和疾病相关特征,患者相关因素,治疗相关因素。在多方面对疾病进行把握,对确定手术、放射治疗方案至关重要。

在回答到“如何衡量临床中将低效治疗组设置为控制组”这个问题时,Prof. Novello 认为,对照组的选择对于研究的成功至关重要。这类型的研究设计鼓励实行应计制,允许患者对药物具有调查权,对潜在的实践结果具有知情权。临床试验可能可以以安全、系统和道德的方式将科学发现纳入到临床实践中。

如果可能,我们应当鼓励患者参与到临床研究中去。科学与临床相结合,各研究机构的大力支持,是我们未来探索创新治疗方案的坚实基础。

Prof. Novello还分享到,我们的工作,是不断地创造更美好的生活。是我们的患者,是他们对于健康生活的渴望一直支持着我们。Prof. Novello 非常记得她的一个患者,叫特蕾莎。当她被诊断为胸腔积液后,她要求能够立刻展开治疗。但是不幸的是,我们认为我们所具备的材料不足以开展分子研究。我们花费了很大的时间和精力来说服这位处在焦虑中的患者做出理性的选择。今天,特蕾莎的身体状态还是不错的。特蕾莎仍然记得她过去花在分子分析上的时间、将所有需要纳入临床试验的程序还有当口服治疗似乎不够时,需要进行的局部治疗。但是今天她认为这一切都是值得的。她说,她终于明白了在选择治疗方案前做好充足准备和调查的重要性。

这每一天的小小成功,都提醒着我们,我们需要的是持续创新。而在追求的过程中,离不开团队的协作、对研究的激情和永不停歇的努力。

  1. We understand you are a world-recognized leader in the field of thoracic oncology, specially in the treatment of mesothelioma. How do you think to choose treatment strategy for malignant pleural mesothelioma? What is the best option from your perspective?

  2. What do you think about the role of adjuvant TKI as adjuvant therapy in completely resected NSCLC? After the results of ADJUVANT trials being launched, what should researchers do to explore the best option for EGFR –sensitizing mutation patients?

  3. How do you design a control group in a clinical trial? As you know, it is helpful to draw a wonderful conclusion if you set an inefficient treatment as a control group, but it seems to be an unethical practice for the recruited participants. What is your opinion?

  4. Along the way to be an excellent researcher, would you like to share with us any stories behind? What encourage you to choose the career/field?


采写编辑:凌晨 AME Publishing Company

特别鸣谢阎石医生对采访问题的指导

comments powered by Disqus

附件